Danish pharma firm Novo Nordisk has announced that it would invest approximately 4 billion yuan (¥) in Tianjin for a sterile preparation expansion project and recently held a groundbreaking ceremony for the expansion project. 

On the day of the event, leaders from the Danish Embassy in China and relevant commissions and bureaus of Tianjin City and Binhai New Area were invited to attend and jointly witnessed the launch of the project.

2024 is the 30th anniversary of the establishment of Novo Nordisk China. Thirty years ago, Novo Nordisk took the first step to establish roots in China in Tianjin, building a Tianjin production plant and making it one of its global strategic production bases. 

In the first quarter of 2023, Novo Nordisk invested 1.18 billion yuan to launch a finished product workshop expansion project and introduced a prefilled injection pen production line. The sterile preparation expansion project invested and constructed this time is another important milestone in Novo Nordisk's development in Tianjin. It will further enhance its production capacity in China and meet the needs of Chinese patients for innovative drugs. 

The expanded sterile preparation production will use the world's leading isolator technology to provide a higher level of sterility guarantee for preparation production. The entire project is scheduled to be completed in 2027.